Form 4: Protagonist Therapeutics CFO Executes Stock Sale

CFO Asif Ali sold 1,750 shares of Protagonist Therapeutics to cover tax obligations related to restricted stock unit vesting.

Summary

• Asif Ali, Chief Financial Officer of Protagonist Therapeutics, Inc. (PTGX), sold 1,750 shares of common stock.
• The transaction occurred on April 20, 2026, at a price of $105.47 per share.
• Following the transaction, the reporting person maintains beneficial ownership of 59,003 shares.
• The sale was executed specifically to satisfy tax withholding obligations resulting from the settlement of restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely for tax compliance and does not reflect a change in management's outlook on the company.

Positives

• The transaction was a routine administrative action to cover tax liabilities rather than a discretionary divestment of holdings.

Negatives

• Reduction in the direct equity stake held by a key executive.

Risks

• None identified; this is a standard regulatory filing for tax-related equity transactions.

Future Outlook

Not applicable as this is a retrospective disclosure of an insider transaction.

Industry Context

StockSavvy.ai notes that insider sales to cover tax withholding obligations are standard practice in the biotechnology sector, where equity-based compensation is a primary component of executive remuneration packages.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for executive tax compliance.
• The volume of shares sold is immaterial relative to the total outstanding shares of the company.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was non-discretionary and small in scale.

Next Steps

• No further actions required by the reporting person regarding this specific transaction.

Key Dates

Keywords

PTGX, Protagonist Therapeutics, Insider Trading, Form 4, CFO, Equity Compensation